PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: azacitidine
Drug: glasdegib
Drug: daunorubicin + cytarabine
Drug: Placebo
Drug: cytarabine
Procedure: HSCT

First Posted Date: 2018-01-31

Last Posted Date: 2023-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 730

Registration Number: NCT03416179

Locations: 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇵🇱
WWCOiT im. M. Kopernika w Lodzi, Lodz, Poland

and more 146 locations

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

Phase 1

Withdrawn

Conditions: Inflammatory Bowel Disease

Interventions: Biological: PF 06687234
Biological: [124I]IB PF 06687234

First Posted Date: 2018-01-30

Last Posted Date: 2020-11-03

Lead Sponsor: Pfizer

Registration Number: NCT03414788

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

Phase 4

Completed

Conditions: Onychomycosis
Tinea Unguium

Interventions: Drug: Tavaborole 5% Topical Solution

First Posted Date: 2018-01-23

Last Posted Date: 2018-04-17

Lead Sponsor: Pfizer

Target Recruit Count: 55

Registration Number: NCT03405818

Locations: 🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸
MedStar Health Research Institute - MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States

and more 9 locations

A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Epoetin Hospira MDV
Drug: Epoetin Hospira SDV

First Posted Date: 2018-01-12

Last Posted Date: 2018-05-17

Lead Sponsor: Pfizer

Target Recruit Count: 68

Registration Number: NCT03398473

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Phase 3

Active, not recruiting

Conditions: mCRPC

Interventions: Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

First Posted Date: 2018-01-10

Last Posted Date: 2024-08-23

Lead Sponsor: Pfizer

Target Recruit Count: 1054

Registration Number: NCT03395197

Locations: 🇺🇸
Cook County Health (CCH), Chicago, Illinois, United States
🇺🇸
John H. Stroger, Jr. Hospital of Cook County/IND Pharmacy, Chicago, Illinois, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 333 locations

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: Placebo PF-06700841
Drug: PF-06651600 Placebo
Drug: PF-06700841
Drug: PF-06651600

First Posted Date: 2018-01-10

Last Posted Date: 2024-10-30

Lead Sponsor: Pfizer

Target Recruit Count: 244

Registration Number: NCT03395184

Locations: 🇺🇦
Regional Municipal Non-profit Enterprise "Chernivtsi Regional Clinical Hospital", Surgery Department, Chernivtsi, Ukraine
🇺🇸
Dothan Surgery Center, Dothan, Alabama, United States
🇺🇸
Gut P.C., dba Digestive Health Specialists of the Southeast, Dothan, Alabama, United States

and more 183 locations

Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2018-01-02

Last Posted Date: 2024-10-21

Lead Sponsor: Pfizer

Target Recruit Count: 1459

Registration Number: NCT03387423

Locations: 🇩🇪
Private Practice Richter, Rostock, Germany
🇩🇪
Private Practice, Templin, Germany
🇩🇪
Private Praxis, Duesseldorf, Nordrhein-westfalen, Germany

and more 84 locations

A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-04965842
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2017-12-29

Last Posted Date: 2019-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03386279

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Safety and Efficacy of Xalkori ROS1

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: crizotinib

First Posted Date: 2017-12-18

Last Posted Date: 2024-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT03375242

Locations: 🇯🇵
Pfizer local country office, Tokyo, Japan

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06865571 Immediate release suspension
Drug: PF-06865571 Slow release MR tablets
Drug: PF-06865571 Fast release MR tablets
Drug: PF-06865571 Immediate release tablets

First Posted Date: 2017-12-13

Last Posted Date: 2018-04-17

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03372044

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy